News & Updates

Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.

Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.

Women with greater adherence to a healthful plant-based diet before pregnancy appear to have a reduced risk of gestational diabetes mellitus (GDM), suggests a recent study. On the other hand, adherence to an unhealthful plant-based diet is not associated with GDM risk.

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.